Vanguard Personalized Indexing Management’s Canaan Creative CAN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28.8K Buy
66,787
+12,885
+24% +$7.53K ﹤0.01% 2101
2025
Q4
$37.2K Buy
53,902
+23,203
+76% +$26.6K ﹤0.01% 1908
2025
Q3
$27.1K Buy
30,699
+2,504
+9% +$1.9K ﹤0.01% 1954
2025
Q2
$17.4K Sell
28,195
-8,965
-24% -$6.3K ﹤0.01% 1916
2025
Q1
$32.6K Sell
37,160
-3,775
-9% -$6K ﹤0.01% 1719
2024
Q4
$83.9K Buy
40,935
+3,702
+10% +$6.25K ﹤0.01% 1637
2024
Q3
$37.6K Buy
37,233
+2,933
+9% +$2.92K ﹤0.01% 1701
2024
Q2
$34.3K Buy
+34,300
New +$36.1K ﹤0.01% 1615
2023
Q4
Sell
-10,930
Closed -$19.9K 1576
2023
Q3
$19.9K Buy
+10,930
New +$25.8K ﹤0.01% 1456

Other funds holding CAN

Vanguard Personalized Indexing Management's CAN Position: Q1 2026 in Review

Vanguard Personalized Indexing Management increased its Canaan Creative (CAN) stake by 24% in Q1 2026, buying an estimated $7.53K and bringing the position to 66,787 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

Vanguard Personalized Indexing Management first reported a position in CAN in Q3 2023 and has held it in 9 quarters since. The position peaked at $83.9K in Q4 2024. 81 funds tracked by Wall St. Rank hold CAN as of Q1 2026.

  • Vanguard Personalized Indexing Management held 66,787 shares of Canaan Creative worth $28.8K as of Q1 2026.
  • Vanguard Personalized Indexing Management bought 12,885 Canaan Creative shares in Q1 2026, an estimated $7.53K.
  • Canaan Creative made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #2101 holding.
  • Vanguard Personalized Indexing Management first reported a position in Canaan Creative in Q3 2023 and has held it in 9 quarters since.
  • Vanguard Personalized Indexing Management's Canaan Creative position peaked at $83.9K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held Canaan Creative as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.